Dongyangguang Pharma (06887.HK): Insulin Degludec/Insulin Aspart Injection has received marketing approval from China's National Medical Products Administration

Zhitong Finance APP News: Sunshine Lake Pharma (06887.HK) announced that the company's independently developed Insulin Degludec/Insulin Aspart Injection has officially received marketing approval from China's National Medical Products Administration (NMPA), covering both pen cartridges and prefilled injection pens.